ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
63,845.80
1.51%
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs Yen
153.055
0.01%
Brent Oil
82.765
0.00%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NYSE
  6. Genesis Healthcare Inc (GEN)

  7. Genesis Healthcare Inc (GEN) ニュース

GEN

Genesis Healthcare (GEN)

Genesis Healthcare Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NYSE:GEN
日付受信時刻ニュースソース見出しコード企業名
2023/01/2420 : 27GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022NYSE:GENGenesis Healthcare Inc
2022/11/1110 : 49TipRanksRBC Capital Keeps Their Hold Rating on Gen Digital (GEN)NYSE:GENGenesis Healthcare Inc
2022/11/1001 : 01GlobeNewswire Inc.Genmab Announces Financial Results for the First Nine Months of 2022NYSE:GENGenesis Healthcare Inc
2022/11/0401 : 45GlobeNewswire Inc.Genmab Improves Its 2022 Financial GuidanceNYSE:GENGenesis Healthcare Inc
2022/10/1819 : 35GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022NYSE:GENGenesis Healthcare Inc
2022/10/0604 : 56GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
2022/08/1100 : 01GlobeNewswire Inc.Genmab Announces Financial Results for the First Half of 2022NYSE:GENGenesis Healthcare Inc
2022/08/0901 : 33GlobeNewswire Inc.Genmab Improves Its 2022 Financial GuidanceNYSE:GENGenesis Healthcare Inc
2022/08/0303 : 46GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
2022/07/2102 : 03GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
2022/07/1919 : 33GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022NYSE:GENGenesis Healthcare Inc
2022/07/1823 : 01GlobeNewswire Inc.Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NYSE:GENGenesis Healthcare Inc
2022/07/1200 : 28GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
2022/07/0123 : 14GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
2022/07/0103 : 24GlobeNewswire Inc.Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)NYSE:GENGenesis Healthcare Inc
2022/06/2023 : 35GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
2022/06/1006 : 17GlobeNewswire Inc.Genmab Commences New Arbitration Under License Agreement With JanssenNYSE:GENGenesis Healthcare Inc
2022/06/0201 : 21GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
2022/05/1200 : 01GlobeNewswire Inc.Genmab Announces Financial Results for the First Quarter of 2022NYSE:GENGenesis Healthcare Inc
2022/04/1919 : 29GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022NYSE:GENGenesis Healthcare Inc
2022/04/1406 : 25GlobeNewswire Inc.Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)NYSE:GENGenesis Healthcare Inc
2022/04/0808 : 44GlobeNewswire Inc.Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License AgreementNYSE:GENGenesis Healthcare Inc
2022/02/2420 : 01GlobeNewswire Inc.Notice to Convene the Annual General Meeting of Genmab A/SNYSE:GENGenesis Healthcare Inc
2022/02/1701 : 00GlobeNewswire Inc.Genmab Publishes 2021 Annual ReportNYSE:GENGenesis Healthcare Inc
2022/01/2520 : 30GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021NYSE:GENGenesis Healthcare Inc
2022/01/0423 : 00GlobeNewswire Inc.Genmab and Synaffix Enter into License Agreement for ADC TechnologyNYSE:GENGenesis Healthcare Inc
2021/11/1101 : 00GlobeNewswire Inc.Genmab Announces Financial Results for the First Nine Months of 2021NYSE:GENGenesis Healthcare Inc
2021/11/0505 : 24GlobeNewswire Inc.Genmab Improves its 2021 Financial GuidanceNYSE:GENGenesis Healthcare Inc
2021/10/1919 : 29GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021NYSE:GENGenesis Healthcare Inc
2021/09/2203 : 22GlobeNewswire Inc.Capital Increase in Genmab as a Result of Employee Warrant ExerciseNYSE:GENGenesis Healthcare Inc
 Showing the most relevant articles for your search:NYSE:GEN

最近閲覧した銘柄

NYSE
AXP
American Express
CCOM
US30
US 30
FX
USDGBP
US Dollar vs Sterling
NYSE
KO
Coca Cola
USOTC
RHHBY
Roche (QX)
USOTC
BASFY
BASF (QX)
NYSE
BAC
Bank of America
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
USOTC
ADDYY
Adidas (QX)
NYSE
XOM
Exxon Mobil
CCOM
US100
US Tech 100
SPI
SP500
S&P 500
AMEX
XLF
Financial Select Sector
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有